Abingworth — Full Portfolio
22 tracked investments · listed companies and verified rows first
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $132M raise · filed Aug 2026
Co-investorsAvego BioScience CapitalTSVCIkarian Capital
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
BoardIsaac Manke(Director)in
Board seatBali Muralidhar· per SEC Form D · $94.8M raise · filed Dec 2020
Co-investorsAccess BiotechnologyRiverVest Venture PartnersACORN BIOVENTURESBoulder VenturesNew Enterprise Associates (NEA)
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatBali Muralidhar· per SEC Form D · $50M raise · filed Oct 2025
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersNorwest Venture PartnersOrbiMed
BiotechSouth San Francisco, US
Grant E Pickering(Executive Officer, Director, Promoter)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)
Board seatKurt von Emster· per SEC Form D · $60.2M raise · filed Mar 2017
Co-investorsFrazier Life SciencesMedicxiPivotal Life SciencesRed Tree Venture
Developing innovative biologic therapeutics with transformative clinical potential.
South San Francisco, US
Board seatKurt von Emster· per SEC Form D · $70.7M raise · filed Feb 2021
Co-investorsSofinnova VenturesKleiner Perkins
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.
BiotechHealthtechCambridge, US
Gary Glick(Mr. Glick is a director and the President of the Issuer.)Gary D. Glick(Founder)H. Martin Seidel(Chief Executive Officer)
BoardJean-Francois Formela(Director)in
Co-investorsAtlas Venture
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)Courtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactGilead SciencesAstellas Venture Management LLCLightstone Ventures
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatBali Muralidhar· per SEC Form D · $315M raise · filed Jul 2026
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAlly Bridge Group+2 more
St. Louis, US
Board seatBali MuralidharNatalie Mount· per SEC Form D · $163M raise · filed Jul 2026
BiotechBasel
Sven Ante Lundberg(Executive Officer)Thomas Woiwode(Director)Pablo Cagnoni(Director)Bradley Bolzon(Director)N. Anthony Coles(Director)Kala Subramanian(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $35M raise · filed Nov 2016
Co-investorsNew Enterprise Associates (NEA)SR One Capital ManagementVersant Venture Capital
GenSight Biologics is a clinical-stage biotechnology company developing gene therapies for retinal and neurodegenerative diseases, using mitochondrial targeting sequence and optogenetics technologies.
BiotechHealthtechParis, FR
Jean-Philippe Combal(Executive Officer)Michael Stephen Wyzga(Director)Thomas Gidoin(Executive Officer)Didier Pruneau(Executive Officer)Florent Gros(Director)Nitza Thomasson(Executive Officer)
Board seatGenghis Lloyd-Harris· per SEC Form D · $25M raise · filed Jul 2015
BiotechSan Diego, US
Fred Manby(Executive Officer, Director)inThomas Miller(Executive Officer, Director)inNeil Josephson(Executive Officer)Michael Secora(Executive Officer)Pete Olson(Executive Officer)Chao Zhang(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $50M raise · filed Apr 2026
Co-investorsNexus Venture PartnersNexus Ventures
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Board seatAndrew Sinclair· per SEC Form D · $200.2M raise · filed Jul 2020
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatBali Muralidhar· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersFidelity InvestmentsIntermediate Capital Group+1 more
Abingworth is a life-sciences investment firm that backs early-stage biopharma and biotech companies, providing capital and operational support to help them develop new therapeutics.
BiotechLondon, GB
Co-investorsModi Ventures
Addition Therapeutics develops genetic medicines using its all-RNA, non-viral, LNP-based PRINT platform, which combines the profile of RNA therapeutics with the durability of gene therapies.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)Matthew Patterson(Director)Lawrence Kong(Executive Officer)Jennifer Lee(Director)Ronald Park(Executive Officer, Director)
BoardJayson Punwani(Director)
Co-investorsSR One Capital ManagementOsage University PartnersPivotal Life Sciences
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesOmega FundsTenmileBiotechnology Value Fund
Pathalys Pharma is a private biopharmaceutical company developing treatments for kidney disease, including upacicalcet, which is in late-stage development.
BiotechHealthtechResearch Triangle Park, US
Co-investorsCatalys PacificOrbiMedSamsara BioCapitalKB Investment
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Lundbeckfonden VenturesPappas CapitalRiverVest Venture Partners
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column Group+3 more
An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.
ConsumerGamingMedia & EntertainmentBridgewater, US
William Duke(Executive Officer)Daniel Pelak(Director)Sean Traynor(Director)Steve LaPorte(Director)Paul Queally(Director)John Barr(Director)
Co-investorsAgate Medical Investments LPHLM Venture PartnersKaiser Permanente VenturesMPM BioImpactPitangoWelsh, Carson, Anderson & Stowe
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.